REFERENCES

1. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12-49.

2. Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325:669-85.

3. André T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383:2207-18.

4. Dienstmann R, García-Galea E, O'Farrell A, et al. Interrogating the immune landscape of microsatellite stable RAS-mutated colon cancer. Mol Oncol. 2026;20:1713-25.

5. Jafarlou M, Jafarlou V, Nouri S, et al. Immunotherapy resistance in colorectal cancer: therapeutic strategies and biomarker-guided approaches. Cancer Cell Int. 2026;26:294.

6. Yousefi M, Amirabadi DG, Javan MR, Khosrojerdi A. Immune escape in colorectal cancer: mechanisms and challenges of immune checkpoint inhibitor resistance. Int Immunopharmacol. 2026;169:115986.

7. Farah H, Polatova D, Rizaev J, et al. Overcoming conditional immune resistance in MSS and pMMR colorectal cancer: a sequential gating framework for immunotherapy. Crit Rev Oncol Hematol. 2026;223:105353.

8. Keivany MR, Shojae Asrami E, Besharatloo M, Latifi H, Barjasteh AH. Advances in immunotherapy for colorectal cancer: overcoming resistance in mismatch repair-proficient tumors. Cancer Cell Int. 2026;26:151.

9. Kang W, Zhang Z, Li W, et al. Breaching the immune-cold barrier in pMMR/MSS metastatic colorectal cancer: emerging strategies beyond standard care. Front Immunol. 2026;17:1773002.

10. Fei J, Cai C, Wu W, Shen H, Han Y, Zeng S. Combination immunotherapy for colorectal cancer: clinical applications, rationale, challenges, and future perspectives. Cell Rep Med. 2026;7:102728.

11. Lee-Six H, Olafsson S, Ellis P, et al. The landscape of somatic mutation in normal colorectal epithelial cells. Nature. 2019;574:532-7.

12. Díaz-Gay M, Dos Santos W, Moody S, et al. Geographic and age variations in mutational processes in colorectal cancer. Nature. 2025;643:230-40.

13. Ogino S, Nowak JA, Hamada T, Milner DA Jr, Nishihara R. Insights into pathogenic interactions among environment, host, and tumor at the crossroads of molecular pathology and epidemiology. Annu Rev Pathol. 2019;14:83-103.

14. Cai R, Zhan W, Lyu X, et al. PTEN deficiency impairs MHC-I-mediated tumour immunity via NRF2-dependent autophagy in microsatellite stable colorectal cancer. Gut. 2026;75:1-4.

15. Zhan W, Fu Y, Liu Y, et al. Cathepsin-D-mediated MHC class I degradation contributes to immune evasion in colorectal cancer. Cell Rep Med. 2026;7:102534.

16. Rousseau B, Bieche I, Pasmant E, et al. PD-1 blockade in solid tumors with defects in polymerase epsilon. Cancer Discov. 2022;12:1435-48.

17. Chua J, Kaur A, Mitchell F, et al. A tumor-intrinsic WNT-inhibitory NOTUM program drives immune resistance in microsatellite stable colorectal cancer. Cell Rep Med. 2026;7:102776.

18. Wei X, Zuo M, Liang Q, et al. Unlocking Wnt's weak spot: glycosylated nanoalbumins to reignite immune responses in MSS-CRC. J Pharm Anal. 2026;16:101412.

19. Wang QL, Chen Z, Lu X, et al. Methionine metabolism dictates PCSK9 expression and antitumor potency of PD-1 blockade in MSS colorectal cancer. Adv Sci. 2025;12:e2501623.

20. Zheng P, Hu Z, Shen Y, et al. PSAT1 impairs ferroptosis and reduces immunotherapy efficacy via GPX4 hydroxylation. Nat Chem Biol. 2025;21:1420-32.

21. Peng W, Yang ZR, Wang Z, Zhao YL, Tan SS. Autophagy inhibition enhances PD-1 blockade efficacy in mismatch repair-proficient colorectal cancer. Cancer Genet. 2026;304-5:41-50.

22. Liao Q, Zhou X, Wu L, et al. Gut microbial metabolite 4-hydroxybenzeneacetic acid drives colorectal cancer progression via accumulation of immunosuppressive PMN-MDSCs. J Clin Invest. 2025;135:e181243.

23. Wilson MR, Jiang Y, Villalta PW, et al. The human gut bacterial genotoxin colibactin alkylates DNA. Science. 2019;363:eaar7785.

24. Cao M, Deng Y, Hao Q, et al. Single-cell transcriptomic analysis reveals gut microbiota-immunotherapy synergy through modulating tumor microenvironment. Signal Transduct Target Ther. 2025;10:140.

25. Rahimi A, Baghernejadan Z, Hazrati A, et al. Combination therapy with immune checkpoint inhibitors in colorectal cancer: challenges, resistance mechanisms, and the role of microbiota. Biomed Pharmacother. 2025;186:118014.

26. Chen Y, Wang YT, Hu JY, et al. Modulating the gut microbiota to enhance immune checkpoint inhibitor efficacy in colorectal cancer: mechanisms, therapeutic strategies, and clinical perspectives. Gut Microbes. 2026;18:2652476.

27. Lin A, Fang X, Zhu L, Mou W, Luo P. Dual role of intratumoral microbiota: from colorectal cancer progression to therapeutic opportunities. J Transl Int Med. 2026;14:345-9.

28. Liu S, Zhang Z, Wang Z, et al. SPP1 drives colorectal cancer liver metastasis and immunotherapy resistance by stimulating CXCL12 production in cancer-associated fibroblasts. Cancer Res. 2026;86:58-79.

29. Iglesias Coma M, Badia-Ramentol J, Martinez-Ciarpaglini C, et al. Stromal biomarker-based framework for identifying pMMR/MSS and dMMR/MSI colorectal cancers with poor outcomes and limited benefit from immunotherapy. Gut. 2026;75:2143-55.

30. Palomar de Lucas B, Ortega M, Camblor DG, et al. Spatial dynamics links PD-L1 and tumor-associated macrophage-enriched niches to immune and mesenchymal states in microsatellite-stable colorectal cancer. Cancers. 2026;18:1288.

31. Su W, Wang H, Zhao S, et al. Cerenkov radiation modulates the extracellular matrix for improved pancreatic cancer chemotherapy. Cell Biomater. 2026;2:100221.

32. Pilié PG, Tang C, Mills GB, Yap TA. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol. 2019;16:81-104.

33. Wang Y, Jia R, Si H, et al. Efficacy and safety of sintilimab plus bevacizumab and CAPOX as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer. BMC Cancer. 2025;25:422.

34. Fukuoka S, Hara H, Takahashi N, et al. Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase 1b trial (REGONIVO, EPOC1603). J Clin Oncol. 2020;38:2053-61.

35. Fakih M, Raghav KPS, Chang DZ, et al. Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer. J Clin Oncol. 2021;39:3560.

36. Fakih M, Sandhu J, Lim D, Li X, Li S, Wang C. Regorafenib, ipilimumab, and nivolumab for patients with microsatellite stable colorectal cancer and disease progression with prior chemotherapy: a phase 1 nonrandomized clinical trial. JAMA Oncol. 2023;9:627-34.

37. Wang F, He MM, Yao YC, et al. Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis. Cell Rep Med. 2021;2:100383.

38. Fakih M, Wang C, Sandhu J, Ye J, Egelston C, Li X. Immunotherapy response in microsatellite stable metastatic colorectal cancer is influenced by site of metastases. Eur J Cancer. 2024;196:113437.

39. Liu C, Nie J, Li S, et al. Electroacupuncture combined with fruquintinib and sintilimab in microsatellite-stable metastatic colorectal cancer: a phase II study. Cancer Lett. 2026;639:218238.

40. Yang Q, Huang YY, Zhang KC, et al. Triplet regimen of metronomic capecitabine plus antiangiogenic drug and PD-1 inhibitor as later-line salvage treatment for patients with MSS/pMMR metastatic colorectal cancer: a retrospective study. MedComm. 2025;6:e70174.

41. Zhang Z, Liu S, Xu T, et al. Tumor suppressor SLC9A2 inhibits colorectal cancer metastasis and reverses immunotherapy resistance by suppressing angiogenesis. J Exp Clin Cancer Res. 2025;44:172.

42. Eng C, Kim TW, Bendell J, et al. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2019;20:849-61.

43. Kawazoe A, Xu RH, García-Alfonso P, et al. Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer: final analysis of the randomized, open-label, phase III LEAP-017 study. J Clin Oncol. 2024;42:2918-27.

44. Morris VK, Parseghian CM, Bahrambeigi V, et al. Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAF V600E metastatic colorectal cancer. Cancer Cell. 2025;43:2106-18.e3.

45. Sun Z, Shi M, Xia J, et al. HDAC and MEK inhibition synergistically suppresses HOXC6 and enhances PD-1 blockade efficacy in BRAF V600E-mutant microsatellite stable colorectal cancer. J Immunother Cancer. 2025;13:e010460.

46. Pei B, Peng S, Chen W, Lai L, Zhou F. Combining cetuximab and immunotherapy for treating MSS/pMMR colorectal cancer: current evidence and challenges. Technol Cancer Res Treat. 2025;24:15330338251334209.

47. Zhu J, Fu S, Zou X, et al. PRMT5 inhibitor synergizes with chemotherapy to induce resembling mismatch repair deficiency and enhance anti-TIGIT therapy in microsatellite-stable colorectal cancer. Adv Sci. 2025;12:e2500271.

48. Zamani P, Barootchi E, Firouzabadi A, et al. Targeting T cell exhaustion in colorectal cancer: emerging roles of LAG-3, TIM-3, and TIGIT signaling in overcoming immunotherapy resistance. Cell Commun Signal. 2026;24:81.

49. Zheng T, Ding C, Lai S, et al. CD160 dictates anti-PD-1 immunotherapy resistance by regulating CD8+ T cell exhaustion in colorectal cancer. Nat Cell Biol. 2025;27:1555-71.

50. Wang XX, Zhu C, Sun Y, et al. Modulating the tumor immune phenotypes by radiotherapy: formulating and validating the combination therapy of radiation, PD-L1, and TIM-3 blockade in colorectal cancer. J Immunother Cancer. 2026;14:e013656.

51. Wang J, Yu S, Qian L, Wu Y, Zhang W, Awadasseid A. Small-molecule inhibitors targeting PD-1/PD-L1 in colorectal cancer: mechanisms, challenges, and clinical prospects. ChemMedChem. 2026;21:e202500738.

52. Sun X, Zhou L, Wang Y, et al. Single-cell analyses reveal cannabidiol rewires tumor microenvironment via inhibiting alternative activation of macrophage and synergizes with anti-PD-1 in colon cancer. J Pharm Anal. 2023;13:726-44.

53. Mestrallet G, Brown M, Vaninov N, et al. Reprogramming T cell-myeloid crosstalk overcomes immune resistance in colorectal cancer. Cell Rep Med. 2026;7:102786.

54. Sang T, Liang A, Zhou H, Qiu W, Shi L, Zhou H. Integrating UPLC-MS/MS bioinformatics and in vivo experiments validation to elucidate the mechanism of Wenzi Jiedu Decoction in suppressing colorectal cancer. Phytochem Anal. 2025;36:1105-17.

55. Tu M, Deng X, Zhou Z, et al. Multifunctional copper-based nanoparticles potentiate colorectal cancer immunotherapy via synergistic metabolic remodeling and cGAS-STING pathway activation. J Nanobiotechnology. 2026;24:359.

56. Pérez-Domínguez F, Quezada-Monrás C, Cárcamo L, Muñoz JP, Carrillo-Beltrán D. Oncolytic viruses as a novel therapeutic approach for colorectal cancer: mechanisms, current advances, and future directions. Cancers. 2025;17:1854.

57. Qi C, Liu C, Peng Z, et al. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial. Lancet. 2025;405:2049-60.

58. McHugh KE, Pai RK, Grant RC, et al. Claudin 18.2 expression in 1404 digestive tract adenocarcinomas including 1175 colorectal carcinomas: distinct colorectal carcinoma subtypes are claudin 18.2 positive. Mod Pathol. 2025;38:100712.

59. Lou E, Choudhry MS, Starr TK, et al. Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer: a first-in-human, single-centre, phase 1 trial. Lancet Oncol. 2025;26:559-70.

60. Shao W, Liu Y, Huang L, et al. Clinical trials of bispecific antibody therapy for colorectal cancer: advanced and next steps. Front Oncol. 2026;16:1758251.

61. Lo YL, Lin HC, Li CY, et al. Functional pH-responsive nanoparticles for immune reprogramming in MSS colorectal cancer via ER stress-induced proteostasis disruption, PD-L1-targeting miRNA, and TLR7 activation. Pharmaceutics. 2025;17:1503.

62. Ott JM, Gassenmaier V, Bitzer M, Schürch CM, Heitmann JS, Hagelstein I. B7-H3: a consistent marker in metastatic colorectal cancer with potential for targeted treatment. Pathol Oncol Res. 2025;31:1612186.

63. Chen H, Chen B, Yang Y, et al. Personalized neoantigen vaccine plus regorafenib increases Rgs2+CD8+ T cells infiltration and reprograms the tumor microenvironment in microsatellite stable colorectal cancer liver metastases. Adv Sci. 2025;12:e08040.

64. D'Alise AM, Willis J, Duzagac F, et al. Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial. Nat Med. 2026;32:1002-11.

65. Passardi A, Sullo FG, Bittoni A, et al. CombiCoR-Vax trial: study protocol for a phase II, single-arm, multicenter trial of sequential pembrolizumab plus dendritic cell vaccine followed by trifluridine/tipiracil and bevacizumab in refractory microsatellite-stable metastatic colorectal cancer. BMC Cancer. 2025;25:1921.

66. Wusiman D, Wang Y, Wang M, et al. Biomimetic nanovaccines in cancer therapy: mechanisms, efficacy, and clinical translation. Mater Today Bio. 2025;34:102116.

67. Zhang Y, Guan H, Liu S, et al. Gamma Knife stereotactic radiotherapy combined with tislelizumab as later-line therapy in pMMR/MSS/MSI-L metastatic colorectal cancer: a phase II trial analysis. Elife. 2025;14:RP103559.

68. Zhao M, Nie J, Ye A, et al. Impaired autophagy by cepharanthine induces immunogenic cell death and enhances anti-PD-1 response in MSS-type colorectal cancer. Oncogene. 2025;44:3171-82.

69. Zhou Z, Li C, Liu J, et al. Nanoparticle-mediated tumor mitochondria-selective iron disruption facilitates cancer immunotherapy. Cell Biomater. 2026;4:100551.

70. Zhou Z, Wang H, Li J, Jiang X, Li Z, Shen J. Recent progress, perspectives, and issues of engineered PD-L1 regulation nano-system to better cure tumor: a review. Int J Biol Macromol. 2024;254:127911.

71. Pizzamiglio M, Soulabaille A, Lahlou W, Pilla L, Zaanan A, Taieb J. Advances and challenges in targeted therapies for HER2-amplified colorectal cancer. Eur J Cancer. 2025;222:115471.

72. Jakab A, Patai ÁV, Darvas M, Tormássi-Bély K, Micsik T. Microenvironment, systemic inflammatory response and tumor markers considering consensus molecular subtypes of colorectal cancer. Pathol Oncol Res. 2024;30:1611574.

73. Bever AM, Hang D, Lee DH, et al. Metabolomic signatures of inflammation and metabolic dysregulation in relation to colorectal cancer risk. J Natl Cancer Inst. 2024;116:1126-36.

74. Li D, Wang Z, Yu Q, et al. Tracing the evolution of sex hormones and receptor-mediated immune microenvironmental differences in prostate and bladder cancers: from embryonic development to disease. Adv Sci. 2025;12:e2407715.

75. Wang X, Pan Q, Li Y, et al. Chemotherapy triggers immune evasion by fostering LEPR+ Kupffer cell differentiation in liver metastases. Cancer Cell. 2026;44:658-75.e12.

76. Galeano Niño JL, Ponath F, Ajisafe VA, et al. Tumor-infiltrating bacteria disrupt cancer epithelial cell interactions and induce cell-cycle arrest. Cancer Cell. 2026;44:166-86.e16.

77. Ogino S, Patel AV, Ugai S, Giannakis M, Ugai T. Unique role of the prospective cohort incident-tumor biobank method in etiological research. Lancet Reg Health Am. 2026;53:101290.